Online inquiry

IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4647MR)

This product GTTS-WQ4647MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR1 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001174063.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2260
UniProt ID P11362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4647MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3954MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ1095MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ3041MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ1892MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ37MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ13461MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ5204MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ11941MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLTA3698A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.